Asset profile
fenoterol/ipratropium bromide
Small molecule
Evidence outlook · lead readout
NCT02182479 · Asthma
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT02182479: This was a randomized, double-blind, placebo-controlled trial (n=631) comparing fenoterol/ipratropium delivered by two different inhaler devices against matching placebos. The primary endpoint, change in FEV1 lung function, was clearly met: active treatment roughly doubled the FEV1 improvement seen with placebo, and the newer inhaler was shown non-inferior to the standard one (p<0.001).
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 60 same-indication; 38 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Fenoterol / Ipratropium Bromide: this drug | Phase 3 | Small molecule | Muscarinic M3 receptor / Beta-2 adrenergic receptor (combination) | ||
| Ipratropium / Albuterol | Phase 3 | Small molecule | Muscarinic M3 receptor / Beta-2 adrenergic receptor (combination) | ||
| Albuterol (Armstrong Albuterol HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol / Budesonide (Airsupra) | Approved | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Albuterol HFA (Armstrong's) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol HFA (Proventil HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol Sulfate (Armstrong) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol Sulfate (Provenetil-HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Aminophylline | Approved | Small molecule | Phosphodiesterase (multi-subtype) | ||
| Beclomethasone (QVAR) | Approved | Small molecule | Glucocorticoid receptor | ||
| Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate | Approved | Small molecule | Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | ||
| Benralizumab (Fasenra) | Approved | Monoclonal antibody | IL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophils | ||
| Budesonide (Pulmicort) | Approved | Small molecule | Glucocorticoid receptor agonist | ||
| Budesonide / Formoterol Fumarate (SYMBICORT) | Approved | Combination | Glucocorticoid receptor; Beta-2 adrenergic receptor | ||
| Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere) | Approved | Small molecule | Glucocorticoid receptor; Muscarinic M3; Beta-2 adrenergic | ||
| Ciclesonide (Alvesco) | Approved | Small molecule | Glucocorticoid receptor |
…and 46 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.